迪瑞医疗(300396.SZ)：吉林证监局对公司采取责令改正措施

Core Viewpoint - The company received a decision from the Jilin Regulatory Bureau of the China Securities Regulatory Commission regarding issues with the recognition of foreign sales order revenues and internal controls [1] Group 1: Regulatory Actions - The company was ordered to take corrective measures due to imprudent revenue recognition related to foreign sales orders [1] - Warning letters were issued to three individuals: Wang Xueming, Niu Dandan, and Zhang Xingyan [1] Group 2: Internal Control Issues - In 2023, the company recognized revenue from certain foreign sales orders without actual customs declaration and faced situations of product returns [1] - The internal controls related to foreign sales were found to be inadequate, with incomplete documentation for some foreign sales orders [1]